Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
Name:
Evans2019_Article_ShouldUnaffe ...
Size:
510.5Kb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
NW Genomic Laboratory hub, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WLIssue Date
2019
Metadata
Show full item recordCitation
Evans DG, Howell SJ, Howell A. Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy? Fam Cancer. 2019 Aug 23.Journal
Familial CancerDOI
10.1007/s10689-019-00142-8PubMed ID
31444676Additional Links
https://dx.doi.org/10.1007/s10689-019-00142-8Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s10689-019-00142-8